AstraZeneca PLC (NYSE: AZN) reported third-quarter 2026 earnings per share (EPS) of 2.79 against an analyst estimate of 2.6, a beat of $0.19 or 7.3%. Revenue was $16.21B against an estimate of $16.00B, or $205.9M above. The beat matters because the stock's 52-week range, from 153.41 to 212.71 USD, is wide. The open question is whether profit margins can recover from their recent swings.
Figures are current as of Oct. 30, 2026 and cover the quarter ended Sept. 30, 2026, unless stated otherwise.
Key facts
- Oct. 30, 2026: AstraZeneca reported EPS of 2.79 versus an estimate of 2.6 (+$0.19, 7.3%) for the quarter ended Sept. 30, 2026.
- Oct. 30, 2026: Revenue was $16.21B versus an estimate of $16.00B (+$205.9M, 1.3%). In the year-ago quarter (Q3 FY2025, ended Sept. 30, 2025), revenue was $15.19B and net income was $2.53B.
- Oct. 30, 2026: On the latest quote, shares were at 187.24 USD, up 7.36%. The 52-week range is 153.41 to 212.71 USD.
- Market value: $290.39B, with a trailing 12-month price/earnings (P/E) ratio of 27.95.
- Next report: Feb. 9, 2027, with an EPS estimate of 2.41 and a revenue estimate of $16.66B.
| Metric | Latest | Comparison |
|---|---|---|
| EPS, quarter ended Sept. 30, 2026 | 2.79 | Estimate 2.6 |
| Revenue, quarter ended Sept. 30, 2026 | $16.21B | Estimate $16.00B; year-ago quarter $15.19B |
| Operating margin, quarter ended June 30, 2026 | 20.6% | 24.3% in the quarter ended June 30, 2025 |
| Free cash flow, quarter ended June 30, 2026 | $2.13B | $1.46B in the quarter ended June 30, 2025 (the gain came from lower capital spending) |
The last two rows use the quarter ended June 30, 2026. Our data feed has not yet loaded the full statements for the September quarter.
What happened
The beat. Both EPS and revenue came in above estimates. Revenue was higher than the $15.19B reported a year earlier. The results table in the company's release shows total revenue up versus the prior year, with product sales the largest component. It also shows revenue from alliances, meaning profit shares from drugs it develops with partners, growing faster than product sales. Headlines from Zacks and Benzinga on Oct. 30 credited cancer medicines with driving the growth.
What EPS means here. The 2.79 is the company's "core" EPS. That is an adjusted figure that leaves out some items, such as amortization of acquired assets and restructuring costs. The release shows the company's unadjusted EPS was lower. It also showed both measures higher than a year earlier. Adjusted figures are the ones analysts' estimates are built on, so the beat is measured on that basis.
Where the sales come from. We don't have a current product-level breakdown, so the most recent detail in our data is old. In the quarter ended June 30, 2023, the largest lines were Farxiga at $1.50B, Tagrisso at $1.49B and Imfinzi at $1.08B. Total Oncology revenue was $4.38B. Cancer drugs were already the biggest group then, and current reports say they still lead growth. Treat the 2023 figures as background, not as today's mix.
The share price. On the latest quote on Oct. 30, shares were up 7.36% at 187.24 USD. That is just above the average analyst price target of 186.67 USD. It is below the 52-week high of 212.71 USD.
Why it matters for investors
Margins are the story, not sales. Sales have grown year over year, with one sequential dip. Profitability has not been smooth. Operating margin (operating profit as a share of revenue) over the five most recent quarters in our data:
| Quarter ended | Revenue | Gross margin | Operating margin | Net income |
|---|---|---|---|---|
| June 30, 2025 | $14.46B | 82.9% | 24.3% | $2.45B |
| Sept. 30, 2025 | $15.19B | 81.6% | 23.6% | $2.53B |
| Dec. 31, 2025 | $15.50B | 79.9% | 19.2% | $2.33B |
| March 31, 2026 | $15.29B | 82.5% | 27.8% | $3.08B |
| June 30, 2026 | $15.38B | 83.6% | 20.6% | $2.51B |
This table shows that revenue grew year over year, with one sequential dip in the March 2026 quarter, while operating margin jumped around. Gross margin, which measures what is left after making the drugs, stayed in a narrow band and reached its highest level in the latest quarter shown. In the June 2026 quarter, gross margin rose while operating margin fell. Net income in that quarter was higher than a year earlier, though operating income was lower.
Free cash flow is up, but lumpy. Free cash flow, the cash left after capital spending, was $2.13B in the quarter ended June 30, 2026. That compares with $1.46B a year earlier, but the gain came from lower capital spending, not stronger operations. Operating cash flow fell from $3.39B to $2.89B, while capital expenditure dropped from $1.92B to $752.9M. Other recent quarters were $1.82B in March, $1.38B in December and $3.41B in the quarter ended Sept. 30, 2025. Buybacks in the latest quarter were small at $46.3M.
The balance sheet carries real debt. As of June 30, 2026, AstraZeneca held $4.96B in cash and short-term investments against $32.20B of total debt. Net debt was $27.31B and shareholders' equity was $50.24B. Its Piotroski score, a 0-to-9 gauge of financial health, is 8. Its Altman Z score, a bankruptcy-risk gauge where higher is safer, is 3.54.
Valuation versus peers.
| Company | P/E | Net margin |
|---|---|---|
| AstraZeneca | 27.95 | 17.0% |
| AbbVie (ABBV) | 83.42 | 9.8% |
| Amgen (AMGN) | 29.09 | 22.9% |
| Bristol-Myers Squibb (BMY) | 13.87 | 18.5% |
| Johnson & Johnson (JNJ) | 41.73 | 16.2% |
AstraZeneca's P/E is below AbbVie's and Johnson & Johnson's and slightly below Amgen's. It is above Bristol-Myers Squibb's. Its net margin sits in the middle of this group. Other trailing 12-month measures are price/sales of 4.75, EV/EBITDA of 15.56 and price/free cash flow of 34.50. The dividend yield is 1.7%.
Analysts. Of 41 ratings, 1 is strong buy, 19 are buy, 15 are hold and 6 are sell, which gives a consensus of "Buy". Price targets average 186.67 USD with a median of 185.00 USD. The range runs from a low of 158.00 USD to a high of 216.00 USD. At the latest quote, the share price is already near the average target.
Our MoonshotScore. Stock Expert AI's MoonshotScore V2 for AstraZeneca is 88.1, rated Exceptional. Its sector-relative pillars are:
- Quality 93 (strong)
- Growth 92 (strong)
- Momentum 67 (middle)
- Safety 62 (weaker)
- Valuation 52 (weakest)
What could go wrong
- Margin volatility. Operating margin fell from 27.8% to 20.6% between the March and June 2026 quarters. If the September figure doesn't show a recovery, the beat looks less durable.
- Valuation. The valuation pillar is the lowest of the five. The stock trades near the average analyst target, so there is less room for disappointment.
- Debt. Net debt of $27.31B limits flexibility if sales slow.
- Dependence on cancer drugs. Press coverage credits oncology with driving growth, so competition, pricing pressure or trial setbacks there could matter for results.
- Restructuring and stock history. A Barron's piece on Oct. 30 described a plan to fix a stalling stock. A CFO interview the same day touched on restructuring. Reorganizations can cost money before they save it.
- Thin forecasts. The coming-quarter consensus figures below each rest on a single analyst, so they are rough guides.
What to watch next
- Feb. 9, 2027: the next report, with an EPS estimate of 2.41 and a revenue estimate of $16.66B.
- Quarter ending March 2027: consensus revenue is $15.97B (range $15.66B to $16.27B) and EPS is 2.71, from 1 analyst. For the quarter ending June 2027, revenue is $16.31B (range $16.00B to $16.61B) and EPS is 2.67, also from 1 analyst.
- Operating margin: whether it holds near the better quarters in the table above.
- Free cash flow: whether it supports debt reduction alongside dividends and buybacks.
- Insider activity: among the most recent insider filings, one open-market purchase and no sales fell in the last 90 days.
Frequently asked questions
Q: Did AstraZeneca beat earnings estimates in Q3 2026?
Yes. For the quarter ended Sept. 30, 2026, AstraZeneca reported EPS of 2.79 against an estimate of 2.6, and revenue of $16.21B against an estimate of $16.00B. Revenue was also higher than the $15.19B in the year-ago quarter.
Q: Why did AstraZeneca stock go up on Oct. 30, 2026?
On the latest quote on Oct. 30, the day the results came out, shares were at 187.24 USD, up 7.36%. Press coverage tied the move to the earnings beat and to growth in cancer medicines. No single cause can be proven from price data alone.
Q: Is AstraZeneca stock expensive compared with other big drugmakers?
It is mid-range. Its trailing P/E of 27.95 is below AbbVie's 83.42 and Johnson & Johnson's 41.73, slightly below Amgen's 29.09, and above Bristol-Myers Squibb's 13.87. Our MoonshotScore gives it a valuation pillar of 52, its weakest area. This is information, not a recommendation.
Sources: Stock Expert AI market data and MoonshotScore (own data); Financial Modeling Prep (FMP) financial statements, estimates and ratings; AstraZeneca's Oct. 30, 2026 results release, and news headlines from Zacks, Benzinga and Barron's for qualitative context only.
This is educational content, not investment advice. Past performance does not guarantee future results.
